CURX NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

Curanex Pharmaceuticals Inc Common Stock · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 0.19 USD
-8.7% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -45.6% below the Trend Line and sits at 0.0% of its 52-week range. The latest completed week returned -8.7%, after a -29.2% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 49/100. Near-term considerations: volume confirmation is below normal; earnings are due in 40d.

Setup score 18 out of 100
Latest Close 0.19 USD 24 Jul 2026
1W Return -8.7% latest completed week
4W Return -29.2% short-term follow-through
12W Return -49.2% quarterly tape
Trend Breadth 0.0% 0 of 48 weeks active
Volume Ratio 0.9x vs 13-week average
What is working
  • No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -8.7% Latest completed week; four-week move -29.2%. Indicator stack 0/0 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 32.89% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 49/100 50 relevant articles in the latest sentiment read. Event risk 40d Next report is scheduled for 08 Sep 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -45.6% below the Trend Line and sits at 0.0% of its 52-week range. The latest completed week returned -8.7%, after a -29.2% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.9x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0112-week average 0.05

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure8/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.01Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -29.2% over four weeks, -49.2% over 12 weeks, and - over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-8.7%
4W-29.2%
12W-49.2%
26W-47.5%
52W-
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.26Latest activity-pressure read.
Pressure change-1113.3%Four-week change in activity pressure.
Leadership-Latest relative-leadership reading.
RS change-Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Dec 2025 Field coverage 52% Model confidence 49%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength65/100Blend of value, momentum, and quality. Underlying universe rank 36; rank 1 is best.
Value57/100Relative valuation strength. Underlying universe rank 44; rank 1 is best.
Quality55/100Profitability and accounting quality. Underlying universe rank 46; rank 1 is best.
Momentum57/100Medium-term price momentum. Underlying universe rank 44; rank 1 is best.
Growth57/100Revenue and earnings growth. Underlying universe rank 44; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-52.3%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
3/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-
Net share repurchases relative to market value.
Shareholder yield
-
Dividend yield plus net buyback yield.
Net debt / EBITDA
1.3x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment49/100

Weighted news tone is neutral across 50 relevant articles.

11 positive · 29 neutral · 10 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings40dNext report is scheduled for 08 Sep 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-98.0%Distance below the 52-week high.
13-week volatility7.3%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher9 of 2617 weeks finished lower.
Best week+45.3%Week of 27 Feb.
Worst week-15.3%Week of 1 May.
Latest week-8.7%Week of 24 Jul.

Shape of recent returns

Strong gains6
Modest gains3
Flat weeks0
Modest losses4
Sharp losses13
Recent vol7.3%13-week weekly-return volatility.
Base vol18.1%52-week weekly-return volatility.
Up/down split17/30Count of positive and negative weeks in the 52-week window.
Average skew11.0% / -12.4%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape19/100

Trend, activity pressure, participation, and risk combine to a 19/100 tape read.

 Indicator analysis22/100

Latest 12-week confirmation: trend 0/12, activity pressure 8/12, relative leadership 0/12.

Activity pressure 0.01; No reversal markers Next-Week ExpectancyNegative 32.89%

Next-week expectancy is negative with a 32.89% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors58/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 50 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment49/100

Weighted news tone is neutral across 50 relevant articles.

Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks Insiders50/100

No recent insider transaction evidence is stored.

 Earnings40d

Next report is scheduled for 08 Sep 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 20260.19 USD-8.7%0.35 USD0.85 USD-0.26-372.3KOff
17 Jul 20260.21 USD-7.7%0.35 USD0.86 USD-0.23-265.4KOff
10 Jul 20260.22 USD-12.6%0.36 USD0.88 USD-0.16-448.7KOff
3 Jul 20260.25 USD-4.0%0.36 USD0.89 USD-0.05-288.4KOff
26 Jun 20260.27 USD-5.2%0.37 USD0.91 USD0.03-364.4KOff
19 Jun 20260.28 USD-12.8%0.38 USD0.92 USD0.22-430.9KOff
12 Jun 20260.32 USD5.9%0.38 USD0.94 USD0.48-551.0KOff
5 Jun 20260.30 USD-8.9%0.39 USD0.95 USD0.72-367.7KOff
29 May 20260.33 USD0.3%0.40 USD0.97 USD1.00-249.2KOff
22 May 20260.33 USD10.4%0.41 USD0.99 USD1.20-263.4KOff
15 May 20260.30 USD-7.0%0.42 USD1.00 USD1.38-360.9KOff
8 May 20260.32 USD-12.7%0.43 USD1.02 USD1.52-870.4KOff
1 May 20260.37 USD-15.3%0.44 USD1.04 USD1.58-635.3KOff
24 Apr 20260.44 USD-3.1%0.46 USD1.06 USD1.55-541.6KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.